Just saw that Lifecore Biomedical inked a deal with Indomo to scale up production of DT-001, their new acne treatment candidate. So basically these guys are developing a self-injection device called ClearPen that delivers triamcinolone acetonide directly into inflamed acne lesions at home. Pretty interesting approach to treating acnes that don't respond to standard topicals.

The partnership means Lifecore will be manufacturing clinical batches to support Phase 2 trials starting this year. What caught my attention is the market angle here - acne affects like 50 million Americans annually but only about 1 million are getting corticosteroid injections for inflammatory acnes. That's a huge gap. If this device makes at-home treatment easier and more consistent, could be a real shift in how people manage severe acnes.

This is actually the second agreement between them, so they've already worked together on formulation stuff. LFCR stock has been trading around $4.76 to $8.98 over the past year, closed at $7.06 last I checked. Curious if this news moves the needle - seems like solid progress for a CDMO company betting on the acne treatment space.